AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL).
基金Supported by Spanish Ministry of Health,Instituto de Salud CarlosⅢ(in part),No.PI10/02135
文摘AIM: To determine the dose-related effects of a novel probiotic combination, I.31, on irritable bowel syndrome (IBS)-related quality of life (IBS-QoL).
